2023 World Conference on Lung Cancer (Posters)-P2.14. Treatment Beyond Progression with Atezolizumab in Extensive-Stage SCLC: Exploratory Analysis from the IMfirst Study

P2.14. Treatment Beyond Progression with Atezolizumab in Extensive-Stage SCLC: Exploratory Analysis from the IMfirst Study - PDF(Abstract)

Back to course

Pdf Summary

This abstract provides an exploratory analysis of the IMfirst study, which investigated the use of atezolizumab (ATZ) in combination with chemotherapy as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). The study aimed to determine the safety and efficacy of continuing ATZ treatment beyond disease progression.<br /><br />The study included 155 patients with ES-SCLC, and the median follow-up was 28.4 months. Of the 118 patients who experienced disease progression, 34.7% did not receive any subsequent therapy, 26.3% continued with ATZ as treatment beyond progression (TBP), and 39.0% received other therapies. ATZ-TBP patients received a median of 3 additional cycles of ATZ after disease progression, and 32.3% received subsequent therapies after a second disease progression.<br /><br />The median overall survival since treatment initiation was 14.3 months for ATZ-TBP patients, 12.6 months for patients receiving other therapies, and 7.3 months for patients who did not receive any subsequent therapy. The median overall survival post-disease progression was 7.2 months for ATZ-TBP patients, 6.1 months for patients receiving other therapies, and 1.7 months for patients who did not receive any subsequent therapy.<br /><br />The median progression-free survival for ATZ-TBP patients was 6.5 months before disease progression and 2.2 months after disease progression. Additionally, 22.6% of ATZ-TBP patients had a post-disease progression progression-free survival higher than the median observed in the study.<br /><br />The study found that ATZ-TBP had a favorable benefit-risk profile, with a low occurrence of ATZ-related serious adverse events. These findings suggest that continuing ATZ treatment beyond disease progression may be beneficial for patients with good clinical status at the time of disease progression.<br /><br />In conclusion, this study provides evidence supporting the use of ATZ as a first-line treatment for ES-SCLC and suggests the potential of continuing ATZ treatment beyond disease progression in selected patients.

Asset Subtitle

Rosario García-Campelo

Meta Tag

Speaker Rosario García-Campelo

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

IMfirst study

atezolizumab

chemotherapy

extensive-stage small cell lung cancer

first-line treatment

disease progression

safety and efficacy

ATZ-TBP

overall survival

progression-free survival